0

524661

WELCURE

img img img img
No Data Available

WELCURE DRUGS & PHARMACEUTICAL Share Price Update

As of the latest trading session, WELCURE DRUGS & PHARMACEUTICAL share price is currently at ₹0.34, which is up by ₹0.00 from its previous closing. Today, the stock has fluctuated between ₹0.34 and ₹0.34. Over the past year, WELCURE DRUGS & PHARMACEUTICAL has achieved a return of -56.25%. In the last month alone, the return has been -10.25%.

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

WELCURE DRUGS & PHARMACEUTICAL fundamentals


  • Market cap (Cr)

    [-]

  • P/E Ratio (TTM)

    [-]

  • Beta

    [-]

  • Book Value / share

    [-]

  • Return on equity

    [-]%

  • EPS (TTM)

    [-]

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    [-]

info icon alternate text
  • Market cap (Cr)

    42.00

  • P/E Ratio (TTM)

    1.21

  • Beta

    1.04

  • Book Value / share

    1.08

  • Return on equity

    3.81%

  • EPS (TTM)

    0.29

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    1.07

info icon alternate text

WELCURE DRUGS & PHARMACEUTICAL Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2025 (Values in Cr)
Revenue 0.00
Operating Expense 0.04
Net Profit 1.07
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.13
EBITDA 1.44
Effective Tax Rate (%) 25.17
Particulars SEP 2025 (Values in Cr)
Revenue 65.62
Operating Expense 54.26
Net Profit 8.50
Net Profit Margin (%) 12.95
Earnings Per Share (EPS) 0.76
EBITDA 11.36
Effective Tax Rate (%) 25.17
Particulars JUN 2025 (Values in Cr)
Revenue 299.91
Operating Expense 268.78
Net Profit 23.30
Net Profit Margin (%) 7.76
Earnings Per Share (EPS) 2.07
EBITDA 31.14
Effective Tax Rate (%) 25.17
Particulars MAR 2025 (Values in Cr)
Revenue 21.21
Operating Expense 20.58
Net Profit 2.54
Net Profit Margin (%) 11.97
Earnings Per Share (EPS) 0.33
EBITDA 2.55
Effective Tax Rate (%) 0.00
Particulars DEC 2024 (Values in Cr)
Revenue 0.88
Operating Expense 0.79
Net Profit 0.04
Net Profit Margin (%) 4.54
Earnings Per Share (EPS) 0.04
EBITDA 0.09
Effective Tax Rate (%) 55.55
Particulars MAR 2025 (Values in Cr)
Revenue 24.55
Operating Expense 23.68
Net Profit 2.17
Net Profit Margin (%) 8.83
Earnings Per Share (EPS) 0.36
EBITDA 2.78
Effective Tax Rate (%) 21.94
Particulars MAR 2024 (Values in Cr)
Revenue 0.00
Operating Expense 0.27
Net Profit -0.17
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -0.13
EBITDA -0.13
Effective Tax Rate (%) 0.00
Particulars MAR 2023 (Values in Cr)
Revenue 0.00
Operating Expense 0.14
Net Profit 0.10
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.08
EBITDA 0.10
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Revenue 0.11
Operating Expense 0.08
Net Profit 0.02
Net Profit Margin (%) 18.18
Earnings Per Share (EPS) 0.02
EBITDA 0.02
Effective Tax Rate (%) 0.00
Particulars MAR 2021 (Values in Cr)
Revenue 0.00
Operating Expense 0.08
Net Profit 0.06
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.05
EBITDA 0.06
Effective Tax Rate (%) 0.00
Particulars MAR 2008 (Values in Cr)
Book Value / Share 5.64
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.42
EBITDA Margin -3.61
Particulars MAR 2007 (Values in Cr)
Book Value / Share 7.23
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.41
EBITDA Margin -0.40
Particulars MAR 2006 (Values in Cr)
Book Value / Share 7.94
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.21
EBITDA Margin -5.76
Particulars MAR 2005 (Values in Cr)
Book Value / Share 9.57
ROE % 3.45
ROCE % 6.33
Total Debt to Total Equity 0.15
EBITDA Margin 4.42
Particulars MAR 2004 (Values in Cr)
Book Value / Share 9.47
ROE % 2.79
ROCE % 5.32
Total Debt to Total Equity 0.24
EBITDA Margin 3.05
Particulars MAR 2025 (Values in Cr)
Book Value / Share 9.12
ROE % 3.81
ROCE % 2.42
Total Debt to Total Equity 1.19
EBITDA Margin 11.73
Particulars MAR 2024 (Values in Cr)
Book Value / Share 1.00
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 0.00
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1.13
ROE % 0.62
ROCE % 0.62
Total Debt to Total Equity 0.00
EBITDA Margin 0.00
Particulars MAR 2022 (Values in Cr)
Book Value / Share 0.08
ROE % 0.16
ROCE % 0.16
Total Debt to Total Equity 0.00
EBITDA Margin 18.18
Particulars MAR 2021 (Values in Cr)
Book Value / Share 0.06
ROE % 0.98
ROCE % 0.98
Total Debt to Total Equity 0.00
EBITDA Margin 46.15
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 0.12
Total Assets 266.97
Total Liabilities 266.97
Total Equity 102.51
Share Outstanding 11
Price to Book Ratio 1.00
Return on Assets (%) 0.81
Return on Capital (%) 0.96
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.02
Total Assets 1.37
Total Liabilities 1.37
Total Equity 1.34
Share Outstanding 1
Price to Book Ratio 3.76
Return on Assets (%) -12.74
Return on Capital (%) -13.04
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.00
Total Assets 1.52
Total Liabilities 1.52
Total Equity 1.51
Share Outstanding 1
Price to Book Ratio 3.56
Return on Assets (%) 6.65
Return on Capital (%) 6.71
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.06
Total Assets 0.09
Total Liabilities 0.09
Total Equity 0.09
Share Outstanding 1
Price to Book Ratio 122.13
Return on Assets (%) 24.35
Return on Capital (%) 25.35
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.04
Total Assets 0.07
Total Liabilities 0.07
Total Equity 0.06
Share Outstanding 1
Price to Book Ratio 31.33
Return on Assets (%) 75.52
Return on Capital (%) 79.44
Particulars MAR 2025 (Values in Cr)
Net Income 2.78
Cash from Operations -222.02
Cash from Investing -0.06
Cash from Financing 222.19
Net change in Cash 0.10
Free Cash Flow -222.01
Particulars MAR 2024 (Values in Cr)
Net Income -0.17
Cash from Operations -0.12
Cash from Investing 0.16
Cash from Financing -0.01
Net change in Cash 0.02
Free Cash Flow -0.12
Particulars MAR 2023 (Values in Cr)
Net Income 0.10
Cash from Operations 0.10
Cash from Investing 0.00
Cash from Financing -0.17
Net change in Cash -0.06
Free Cash Flow 0.10
Particulars MAR 2022 (Values in Cr)
Net Income 0.02
Cash from Operations 0.01
Cash from Investing 0.00
Cash from Financing 0.00
Net change in Cash 0.01
Free Cash Flow 0.01
Particulars MAR 2021 (Values in Cr)
Net Income 0.05
Cash from Operations 0.04
Cash from Investing 0.00
Cash from Financing 0.00
Net change in Cash 0.04
Free Cash Flow 0.04
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 28.58 12.37 1.48 219.02 23.12 / 52.00
BLISS GVS PHARMA LTD 217.80 20.82 2.03 2304.08 105.05 / 225.00
CIPLA LTD 1330.85 22.61 3.26 107503.49 1283.00 / 1672.20
FERMENTA BIOTECH LIMITED 310.90 10.34 2.34 915.01 219.00 / 399.00
GLAXOSMITHKLINE PHARMA LT 2593.90 43.69 25.73 43942.23 1968.00 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 28.58 23.24 3.98 219.02 23.12 / 52.00
AMRUTAJAN HEALTH LTD 632.15 31.61 5.34 1827.59 548.05 / 789.95
ASTRAZENECA PHARMA IND LT 8878.75 106.70 27.78 22196.88 6501.60 / 10653.05
BLISS GVS PHARMA LTD 217.80 29.67 2.08 2304.08 105.05 / 225.00

WELCURE DRUGS & PHARMACEUTICAL shareholding pattern

Holding

100.0%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)

WELCURE DRUGS & PHARMACEUTICAL Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
0.34 -2.85 redarrow
red-green-graph indicator
3 Bearish
13 Bullish
  • 5 Days 0.40
  • 26 Days 0.40
  • 10 Days 0.30
  • 50 Days 0.40
  • 12 Days 0.30
  • 100 Days 0.50
  • 20 Days 0.40
  • 200 Days 0.60
0.35 PIVOT

First Support

0.35

First Resistance

0.35

Second Support

0.35

Second Resistance

0.35

Third Support

0.35

Third Resistance

0.35

RSI

45.86

ADX

62.78

MACD

-0.01

Williams % R

-22.22

Commodity Channel Index (CCI)

43.77

Date

2026-02-16

Week

3272567.00

Same Day

2611071.00

Month

4969760.00

1 Year

1.05

3 Year

0.71

Over 1 Month

-10.25%

down

Over 1 Year

-56.25%

down

Over 3 Months

-39.65%

down

Over 3 Years

-6.63%

down

Over 6 Months

-67.59%

down

Over 5 Years

11.84%

down

WELCURE DRUGS & PHARMACEUTICAL Corporate Actions

Ex-Date Ex-Bonus Ratio
16 Oct 2025 16 Oct 2025 1:10
Ex-Date Old FV NEW FV Record Date
16 Oct 2025 10.0 1.0 16 Oct 2025

Top Gainers

WELCURE DRUGS & PHARMACEUTICAL Share Price

Incorporated on 4 Jun.'92, Welcure Drugs And Pharmaceuticals (WDPL) was promoted by D C Jain, Sanjeev Jain and Sandeep Jain. The promoters have interests in other companies such as Paam Pharmaceuticals, Pioneer Products, Alirox Abrasives, A K Laboratories, etc.

WDPL had come out with a Rs 4-cr public issue in Aug.'94 to part-finance the Rs 7-cr project to manufacture bulk drugs in Rajasthan and finance investments in a subsidiary, A K Laboratories (AKL). The company has also submitted the letter of offer for a Rs 7.09-cr rights issue of equity shares in Jan.'96 to finance its expansion programmes.

Products of WDPL include bulk drugs such as ampicillin and trimethoprim, drugs intermediates and pharmaceutical formulations. It has decided to add amoxycillin and cloxacillin to its range with provision to manufacture ibuprofen. It manufactures over a hundred varieties of tablets, capsules and dry syrups, sulpha drugs, vitamins, analgesics, etc. Its subsidiary, AKL, manufactures 6-APA, a key drug intermediate in the manufacture of semi-synthetic penicillin.

The company has decided to set up new sections of paediatrics and veterinary drugs and to diversify into ointments and liquid syrups.

The new products of the company WELSTAP , X- CLOX , ETHAMBUTOL, RIFA- Z , CETIRIZIN , NORTIN have been well accepted in the market.

The Company has entered into a collaboration agreement with a russian company to act as their sole selling agent for a unique medicine Stevioside, an alternate to sugar, Saccharin and Aspartame.

The Company has added a new liquid oral plant in Bhiwadi, Rajasthan. It has obtained ISO 9002 certification with double accredition from ABS Quality Evaluation Inc Texas and by Registrar of Accredition Board of USA. Welcure has also entered into an agreement with Bihar Drugs and Chemicals Ltd, a government of Bihar undertaking, for manufacturing their products in its factory on loan basis.

During the year 2000-01 the company had launched some products like CEZEN,DIMCIN PLUS,OXIN,SPASWIN etc.The company has entered into technical collaboration agreement with Advanced Medical Care Inc New Jersey USA for setting up of joint venture facilities in the existing plant of the company.

During the year 2001-02, the company had launched products like B-ZEX, DMART PLUS, DRALPIN, DUKESPAS, DUBAMOL, HISTACURE, KUFFWEL, KINGSPAS, LANAX, PETRIMAX, PEEROSCAM, RENACT, SARVO, WELCEE, WELGESIC, WELIC, WELOXY, WELRELEEF, X-DRYL. It changed its marketing policy from 'Sales through Wholesale Distributors' to ' Sales at Doorstep' by reaching every corner of the country and by putting dual force on Sales-through sales personnel on one hand and through stockists and distributors on the other hand.

The Company is carrying on the business of manufacturers, designers, repairers, installers, merchants, importers, exporters, agent for sale and distributors of and dealers in water processing equipment and purifiers, and water softeners of every description. Apart from these, it deals in real estate and engaged in creating exceptional living and working spaces for the new Indian global professionals.

Parent organization Indian Private
NSE symbol [-]
Founded 1996
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Welcure Drugs & Pharmaceuticals Ltd?

Answer Field

Welcure Drugs & Pharmaceuticals Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 0.34 as on Feb 17 2026 03:30 PM.

What is the Market Cap of Welcure Drugs & Pharmaceuticals Ltd Share?

Answer Field

The market cap of Welcure Drugs & Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 42.00 as on Feb 17 2026 03:30 PM.

What is the 52 Week High and Low of Welcure Drugs & Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Welcure Drugs & Pharmaceuticals Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 1.44 and ₹ 0.28.

What is 1 year return for Welcure Drugs & Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been -56.25%.

What is the P/E Ratio of Welcure Drugs & Pharmaceuticals Ltd Share?

Answer Field

As on Feb 17 2026 03:30 PM the price-to-earnings (PE) ratio for Welcure Drugs & Pharmaceuticals Ltd share is 1.21.

What is the PB ratio of Welcure Drugs & Pharmaceuticals Ltd Share?

Answer Field

As on Feb 17 2026 03:30 PM, the price-to-book (PB) ratio for Welcure Drugs & Pharmaceuticals Ltd share is 1.08.

How to Buy Welcure Drugs & Pharmaceuticals Ltd Share?

Answer Field

You can trade in Welcure Drugs & Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Welcure Drugs & Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Welcure Drugs & Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Welcure Drugs & Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59